Drug Trial Radar · NCT00003057
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 26, 1997
Primary completion
May 2000
Sponsor
- Lead sponsor
- Eastern Cooperative Oncology GroupResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); SWOG Cancer Research Network; Cancer and Leukemia Group B
- First posted
- Jul 19, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs such as octreotide and loperamide hydrochloride use different ways to relieve the diarrhea caused by chemotherapy. PURPOSE: Randomized phase III trial to compare the effectiveness of octreotide with loperamide hydrochloride for the treatment of chemotherapy-related diarrhea in patients who have colorectal cancer.
Conditions
- Colorectal Cancer
- Diarrhea
Interventions
loperamide hydrochlorideDrug
octreotide acetateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego Cancer Center
La Jolla, California
UCSF Cancer Center and Cancer Research Institute
San Francisco, California
CCOP - Christiana Care Health Services
Wilmington, Delaware
Walter Reed Army Medical Center
Washington D.C., District of Columbia
CCOP - Mount Sinai Medical Center
Miami Beach, Florida
University of Illinois at Chicago Health Sciences Center
Chicago, Illinois
University of Chicago Cancer Research Center
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
University of Minnesota Cancer Center
Minneapolis, Minnesota
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri
Barnes-Jewish Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada
Norris Cotton Cancer Center
Lebanon, New Hampshire
CCOP - North Shore University Hospital
Manhasset, New York
North Shore University Hospital
Manhasset, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
New York Presbyterian Hospital - Cornell Campus
New York, New York
Mount Sinai Medical Center, NY
New York, New York
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York
State University of New York - Upstate Medical University
Syracuse, New York
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina
Duke Comprehensive Cancer Center
Durham, North Carolina
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina
Rhode Island Hospital
Providence, Rhode Island
Medical University of South Carolina
Charleston, South Carolina
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee
Vermont Cancer Center
Burlington, Vermont
MBCCOP - Massey Cancer Center
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.